

Abstract

- Nectin Therapeutics is a clinical-stage biotechnology company and a trailblazer in oncology drug development, focusing on addressing unmet needs in cancer treatment. Its lead product, NTX1088, is a first-in-class immune checkpoint inhibitor (ICI) directed against PVR, a novel target overexpressed in the majority of solid tumors. NTX1088 demonstrates superior standalone activity compared to existing ICIs and has the potential to enhance and revamp clinical responses to existing therapies by invigorating the immune system to fight cancer. Currently, NTX1088 is being evaluated as a monotherapy and in combination with the anti-PD1 inhibitor Keytruda in a phase I trial for patients with advanced solid tumors.
- Additionally, Nectin is developing a diverse pipeline of first- and best-in-class therapies, including antibody-drug conjugates (ADCs) that are showing superiority over approved and clinically explored ADCs.
- Nectin's dedication to innovation and excellence has earned recognition from prestigious organizations, including the Cancer Focus Fund, MD Anderson Cancer Center, and Merck MSD, who have funded and are collaborating with the company to advance its phase 1 trial. The company's pipeline of novel and potent therapies has attracted investment from top investors in the field, including Integra Holdings, aMoon, Peregrine Ventures, and IBF.